Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com   SPECIAL REPORT #20.13   Remdesivir meets primary endpoint in pivotal COVID-19 study       Gilead announces that the pivotal, placebo-controlled study of remdesivir conducted at the National Institute of Allergy and Infectious Diseases (NIAID) had met its primary endpoint. The company also released data […]

  Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com   SPECIAL REPORT #20.12     Coronavirus Treatment Tracking       Kevzara from Sanofi and Regeneron and Actemra from Roche are both selective interleukin- 6 (IL-6) inhibitors, approved for the treatment of rheumatoid arthritis, which have recently been tentatively repurposed to treat COVID-19.   Yesterday […]

  Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com   SPECIAL REPORT #20.11     Remdesivir trials on hold in China       Having to stop the development of a clinical candidate because the disease seems to disappear while studies are ongoing is one of the most awkward situation a biopharmaceutical company can face. […]

  Due to COVID-19 Pandemia, the BIO International Convention will transition to a new, virtual event format, BIO Digital , June 8-12, 2020. You have only limited time to prepare the business convention  and We provide services for the preparation for the Bio one-to-one Partnering: screening potential customers, partners for your technology or therapeutic molecules to license or your services […]

  Btobioinnovation.com Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation  jcm9144@gmail.com     SPECIAL REPORT #20.10     COVID-19: The Lockdown       Dear Readers, Dear Friends   First of all, I wish you are all doing fine, most probably as I am, in a strict confinement to avoid the spread of COVID-19 pandemic. I guess […]